Twist Bioscience Corp
Change company Symbol lookup
Select an option...
TWST Twist Bioscience Corp
GRTS Gritstone bio Inc
QTWO Q2 Holdings Inc
DNAB Social Capital Suvretta Holdings Corp II
UPST Upstart Holdings Inc
GILT Gilat Satellite Networks Ltd
LAIXY LAIX Inc
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
OXBR Oxbridge Re Holdings Ltd
NVO Novo Nordisk A/S
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Twist Bioscience Corporation is a synthetic biology and genomics company. The Company has developed a Twist Bioscience DNA synthesis platform to industrialize the engineering of biology. The core of its platform is a technology that provides a new method of manufacturing synthetic DNA by writing DNA on a silicon chip. The Company utilizes its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. It consists of two product lines, synthetic biology tools and NGS tools, that address different needs of its customers across a range of applications, such as synthetic genes, oligo pools, SARS-CoV-2 tools, and DNA libraries. Its synthetic biology products include Synthetic genes and gene fragments, Oligonucleotide, or Oligo pools for CRISPR gene editing. The NGS products are used for diagnostic tests for various indications like SARS-CoV-2.

Closing Price
$35.24
Day's Change
-0.54 (-1.51%)
Bid
--
Ask
--
B/A Size
--
Day's High
38.15
Day's Low
35.18
Volume
(Light)
Volume:
734,179

10-day average volume:
932,770
734,179

Company Profile

Twist Bioscience Corporation is a synthetic biology and genomics company. The Company has developed a Twist Bioscience DNA synthesis platform to industrialize the engineering of biology. The core of its platform is a technology that provides a new method of manufacturing synthetic DNA by writing DNA on a silicon chip. The Company utilizes its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. It consists of two product lines, synthetic biology tools and NGS tools, that address different needs of its customers across a range of applications, such as synthetic genes, oligo pools, SARS-CoV-2 tools, and DNA libraries. Its synthetic biology products include Synthetic genes and gene fragments, Oligonucleotide, or Oligo pools for CRISPR gene editing. The NGS products are used for diagnostic tests for various indications like SARS-CoV-2.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
10.36x
Price/Book (MRQ)
2.32x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

September 2022
Current Month
6.2M
Previous Month
6.0M
Percent of Float
11.90%
Days to Cover
7.0619 Days

Share Information

TWST is in a share class of common stock
Float
52.5M
Shares Outstanding
56.4M
Institutions Holding Shares
293
98.49%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Emily M. LeproustChmn.
  • James M. ThorburnCFO
  • Dennis ChoSr.VP
  • William BanyaiSr.VP
  • Paula GreenSr.VP

Address

Insider Trading

During the most recent quarter, 9K shares were bought, and 51K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.